

Product Datasheet

AC220

Catalog No. **BP-02113** · CAS **950769-58-1** · Form **free base** · Physical state **solid** · Color **White to light yellow** · Version **1.0** · Revision **2026-09-02**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target FLT3; Apoptosis; PDGFR; c-Kit	Research area Cancer
--	--------------------------------

Molecular formula **C₂₉H₃₂N₆O₄S**

Molecular weight **560.6670**

STRUCTURE



DESCRIPTION

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a K_d of 1.6 nM.

BIOLOGICAL ACTIVITY

Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a K_d of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC₅₀s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis.

SOLUBILITY

Soluble in DMSO/DMF

REFERENCES

- [1]. Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 2009, 114(14), 2984-2992.
- [2]. Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25(2):226-42.
- [3]. Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.